Clinical Trials Directory

Trials / Completed

CompletedNCT02121678

Effect of Resistance and Aerobic Exercise in CIDP or MMN

Effect of Resistance and Aerobic Exercise on Muscle Strength, Aerobic Capacity and Quality of Life in Patients Treated With Immunoglobulin for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) or Multifocal Motor Neuropathy (MMN)

Status
Completed
Phase
N/A
Study type
Interventional
Enrollment
23 (actual)
Sponsor
University of Aarhus · Academic / Other
Sex
All
Age
18 Years – 80 Years
Healthy volunteers
Not accepted

Summary

Resistance and aerobic exercise has been shown to be effective for maintenance of muscle strength in patients with neuromuscular diseases. Exercise in CIDP and MMN is sparsely described. The aim of the study is to evaluate changes in muscle strength during high intensive resistance training and changes in maximal oxygen consumption (VO2-max) during high intensive aerobic training in patients with CIDP or MMN in maintenance therapy with subcutaneous immunoglobulin. The hypotheses are that muscle strength and VO2-max are significantly increased during the training sessions.

Conditions

Interventions

TypeNameDescription
OTHERResistance trainingParticipants do resistance training of selected muscle groups. Resistance are predefined from 1-repetition max (1-RM) and increased during the 12 weeks of training: * Week 0-4: 70-80 % of 1-RM * Week 5-8: 75-86 % of 1-RM * Week 9-12: 80-92% of 1-RM Participants trains unilateral, the opposite site serves as reference. * MMN patients train elbow (flexion/extension) and wrist (flexion/extension) * CIDP patients train knee (flexion/extension) and elbow (flexion/extension)
OTHERAerobic trainingParticipants train on ergometer bicycle 2 times weekly increasing during the first weeks to 3 times weekly. Workload is measured before initiation and VO2-max, heart rate and blood pressure will be measured as well. Patients train with 60-75 % of VO2-max for 30 minutes per training session. They use heart rate monitor to store data.

Timeline

Start date
2014-04-01
Primary completion
2015-12-01
Completion
2016-01-01
First posted
2014-04-23
Last updated
2016-05-12

Locations

2 sites across 1 country: Denmark

Source: ClinicalTrials.gov record NCT02121678. Inclusion in this directory is not an endorsement.